San Diego, California – October 17, 2016 – AltheaDx, Inc. (“AltheaDx” or the “Company”), a commercial stage molecular diagnostics company specializing in the field of personalized medicine, today announced the appointment of Mr. Andrew Jackson as Chief Financial Officer.
Mr. Jackson joins us with over 20 years of finance experience. Prior to joining AltheaDx, Mr. Jackson was Chief Financial Officer and Principal Accounting Officer of Celladon Corporation, a publicly traded, clinical stage biotechnology company. During his time at Celladon, Mr. Jackson scaled the company through its growth and led Celladon’s public company compliance following its Initial Public Offering and completed the company’s accretive merger with Eiger Biopharmceuticals. Prior to Celladon, Mr. Jackson held senior finance positions at various life science and technology companies where he had extensive experience with mergers & acquisitions, treasury management, capital & debt financing and financial planning. He holds a B.S.B. in Accounting from the University of Minnesota, an M.B.A in Finance from San Diego State University and is a Certified Public Accountant.
“We are pleased to welcome Andrew to the executive leadership team of AltheaDx,” said Jorge Garces, President and Chief Executive Officer. “He has a proven track record with both venture-backed and public companies and will provide the leadership and strategic vision required as we grow our business.”
AltheaDx is a commercial stage molecular diagnostics company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. AltheaDx’s IDgenetix® pharmacogenetic testing portfolio addresses some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. AltheaDx is a CAP-accredited, CLIA-certified laboratory located in San Diego, CA. For more information, visit www.altheadx.com.
Forward Looking Statements
This press release may contain forward-looking statements regarding the business strategy of AltheaDx. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity or performance to differ materially from those expressed or implied by these forward looking statements. These statements reflect the views of AltheaDx as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.